If you are a consumer founder trying to raise funds in India in 2026, the market is neither open nor closed — it is selective. India's private consumption sits at roughly 61.5% of GDP, the highest since FY12, growing about 7% in real terms, and FMCG alone stood at about US$289 billion in 2025. Yet D2C funding fell from a $1.6B peak in 2022 to $756.6M across 251 rounds in 2024. Capital did not leave the consumer sector; it moved to brands that can prove profitability and repeat purchase.
The short version. The three most fundable consumer categories for a ₹1–20 Cr seed or Series A raise right now are health and wellness / functional nutrition, differentiated premium and clinical beauty, and pet care. Mass skincare D2C, generic health snacking, and celebrity-led fashion are overcrowded. Exits are finally real — HUL completed the ₹2,706.44 Cr Minimalist acquisition in April 2025, and FirstCry and Wakefit are public — which is what has brought family offices and strategics back to the table.
1. The macro is a tailwind, but consumption is K-shaped. Real GDP is estimated at 7.4% for FY26, with Q2 FY26 surprising at 8.2%. But Blume's Indus Valley Report 2025 found roughly 90% of the population lacks meaningful discretionary flexibility, and India's top 10% — a group about the size of Mexico — drives an estimated 66–67% of discretionary spend. Per-capita consumption (~$1,493 in 2023) still trails China's 2010 level. For founders, this means premiumisation is a real but narrow wedge: pick the affluent narrow lane or the value-mass lane deliberately, and say so in your deck.
2. Funding has bifurcated into discipline capital. Tracxn's 2024 data shows D2C funding at $1.6B/374 rounds (2022) → $929.7M/327 rounds (2023) → $756.6M/251 rounds (2024), with 70 first-time-funded companies, 13 acquisitions, 3 IPOs and zero unicorns. Seed and early-stage funding rose while late-stage fell. Dry powder is abundant — multiple consumer-dedicated funds closed in 2024–25 — so a good seed-stage consumer brand can still raise. What has disappeared is capital for growth-at-any-cost.
3. Quick commerce is the biggest structural shift for consumer brands. Blinkit held about 48% of India's quick-commerce market in 2025, ahead of Swiggy Instamart (~24%) and Zepto (~22%); together they control over 90% of a market that crossed $6–7B GMV. Q-commerce is now a media channel as much as a distribution one — the three platforms pulled in roughly ₹3,000–3,500 Cr in ad revenue in FY25. Discovery has moved from your own website to the platform shelf. That accelerates trial for new brands and compresses the classic D2C moat, and investors will ask how your contribution margin survives platform ad inflation.
4. Exits have finally validated the category. HUL closed its acquisition of Minimalist's parent, Uprising Science, on 22 April 2025 for ₹2,706.44 Cr — a 90.5% all-cash stake at a ₹2,955 Cr pre-money enterprise value, for a brand that crossed a ₹500 Cr revenue run-rate in about four years. Wakefit and FirstCry listed; The Souled Store acquired Redwolf and is IPO-bound. For the first time, Indian consumer investors have a credible exit map.
FMCG and packaged foods. IBEF puts the market at US$289.12B in 2025, heading to US$642.87B by 2030 at a 17.3% CAGR, with new-age brands growing more than three times faster than the market. Rural volume growth (8.4% YoY) is outpacing urban (2.6%). F&B remains the hottest D2C sub-sector for VCs — Fireside, DSG and Sauce.vc are the most active — but gross margins of 30–45% mean repeat rate and distribution economics decide the round.
Functional beverages. India's functional drinks market is about $3.79B (2024) heading to $7.36B by 2030 at ~11.7% CAGR, with nutraceutical drinks around 70% of the segment. Sugar reduction is structural — Varun Beverages reported over 55% of 2025 volumes from low- or no-sugar products — and FSSAI's 2024 nutraceutical regulation update created clearer health-claim pathways. Investor appetite here is active and thematic.
Beauty and personal care. India BPC is roughly $24–28B, heading toward $34B by 2030. In skincare, mass (<₹200) is about 40% share and legacy-dominated; mass-premium (₹200–500) is crowded with Mamaearth, The Derma Co and WOW; mid-premium (₹500–1,500) is the highest-growth tier at ~18% CAGR. The genuinely underserved tier is ₹1,500–3,000 dermatologist-backed clinical skincare, along with men's grooming, haircare and intimate hygiene. Appetite is active — but only with clinical or ingredient differentiation.
Health, wellness and nutrition. Nutraceuticals sit at ~$6.1–8B (2024), projected to $18–21B by 2030–2033 at 11–12% CAGR; dietary supplements are ~₹201B growing 12.3%. The 18–35 cohort is the core buyer, men's health is the fastest-growing sub-segment, and subscription mechanics give this category the recurring revenue investors are paying up for.
Pet care. Packaged pet-food penetration in India is only about 10%, versus 25–30% in China and over 80% in the US — that gap is the entire bull thesis. Supertails raised a $15M Series B, Heads Up For Tails was reportedly closing ~$25M in late 2025, and Godrej committed ₹500 Cr over five years. Active investors, uncrowded cap tables.
Where appetite is cooling. Home care is capital-intensive and dominated by HUL, P&G, Reckitt and Godrej. Baby and kids has consolidated around FirstCry and Honasa, with white space only in premium toxin-free care and baby nutrition. Fashion is the hardest sell — 55–65% gross margins are achievable but 20%+ return rates keep net margins thin, so only capital-efficient omnichannel brands like Snitch and The Souled Store are clearing. Cloud kitchens were punished in the correction; profitable café and franchise-led formats are attracting capital again.
Cheque sizes by stage. For Indian consumer: seed roughly ₹2–14 Cr; Series A about $3–10M; Series B $15–40M; growth $40M and above. Active funds with fresh dry powder include Fireside (Fund IV, ~₹2,265 Cr, Dec 2025), Sixth Sense (Fund III ₹2,603 Cr), RPSG Capital Ventures (Fund II ₹550 Cr, ₹10–40 Cr cheques), Titan Capital, Atomic Capital (₹400 Cr maiden fund, Aug 2025), Kairon Capital (₹200 Cr, ₹2–14 Cr cheques) and family offices such as Sharrp Ventures.
Valuation reality. The single most common misalignment we see is beauty and fashion founders anchoring on 2021-era 10–15x revenue multiples. The market has reset to roughly 2–5x revenue for growth D2C and 8–18x EBITDA, with 20x+ reserved for defensible strategic targets carrying 40%+ gross margins. Indian D2C multiples compressed 30–50% from peak. Pricing your round off contribution margin and repeat rate, not hype, is now the difference between a closed round and a six-month process.
The screen investors apply. Before a term sheet, expect to be tested on: 55%+ gross margin, contribution-margin-positive unit economics, LTV:CAC of at least 3:1, CAC payback under six months, a repeat rate above 30%, and a credible path to ₹100 Cr revenue. Marketplace-heavy brands should reconcile GMV against net revenue explicitly — investors will do it anyway.
India versus China, and what arrives next. India today resembles China circa 2006–2010 on per-capita GDP — the classic discretionary inflection. We trail China's consumption maturity by 10–15 years, but we are leapfrogging in quick commerce, UPI payments and social commerce. The Western trends most likely to land here in the next three to five years: GLP-1 and weight-management consumer products, gut-health and functional beverages, premium pet nutrition, better-for-you packaged foods, men's wellness, and sleep and longevity products. If you are building in one of those, you are early in the right way.
What this means if you are raising. Build your raise around evidence, not narrative: category selection that matches live investor appetite, unit economics that survive quick-commerce ad inflation, and a valuation ask inside the post-correction band. Eone Capital works with Indian consumer founders on exactly this — category positioning, investor mapping, and warm introductions into the funds and family offices currently deploying. If you are raising ₹1–20 Cr, request a free evaluation and we will tell you honestly where you sit against the screen above.
Sources: IBEF, Tracxn 2024 Geo Annual Funding Report, PIB First Advance Estimates, Blume Indus Valley Report 2025, Grand View Research, IMARC, Reuters/Datum Intelligence, DealStreetAsia, Hindustan Unilever disclosures, Inc42 and Business Standard reporting. Figures are as reported by those sources and are indicative, not investment advice.
Find out where your business sits against this filter.
Eone Capital is a specialist fundraising advisory for Indian consumer-facing businesses raising ₹50 lakh to ₹20 crore from HNIs, family offices, angels, and institutional funds. The evaluation is free.